Scarica l'app Stockscreener
10.35
0.39%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$10.31
Aprire:
$10.36
Volume 24 ore:
5.04M
Relative Volume:
0.55
Capitalizzazione di mercato:
$12.07B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-3.265
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+1.77%
1M Prestazione:
+6.59%
6M Prestazione:
+28.89%
1 anno Prestazione:
-9.84%
Intervallo 1D:
$10.34
$10.50
Intervallo di 1 settimana:
$10.13
$10.52
Portata 52W:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.35 | 12.02B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
145.94 | 64.88B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.01 | 44.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.25 | 41.72B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.82B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
418.58 | 19.28B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Can volume confirm reversal in Viatris Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
What’s the recovery path for long term holders of Viatris Inc.Weekly Risk Summary & Entry Point Confirmation Signals - newser.com
Will Viatris Inc. stock return to pre crisis levels2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Is Viatris Inc. stock a good choice for value investorsInsider Buying & Low Risk Entry Point Guides - newser.com
Will Viatris Inc. stock benefit from upcoming earnings reportsJuly 2025 Snapshot & Target Return Focused Picks - newser.com
Should you wait for a breakout in Viatris Inc.July 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Viatris updates bylaws and sets 2026 annual meeting for May 15 - Investing.com Canada
What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter - The Motley Fool
Viatris updates bylaws and sets 2026 annual meeting for May 15 By Investing.com - Investing.com South Africa
Viatris Inc ($VTRS) CEO 2024 Pay Revealed - Quiver Quantitative
Viatris Announces Approval of Amended Bylaws - TipRanks
Viatris says second phase 3 trial of blurred vision drug meets goal - MSN
What You Need to Know Ahead of Viatris' Earnings Release - Yahoo Finance
Truist Initiates Viatris (VTRS) Coverage with Buy Rating, $15 PT - MSN
Postmenopausal Osteoporosis Market Booming with Rapid Growth - openPR.com
Can Viatris Inc. (VIA) stock sustain double digit ROEPrice Action & AI Forecasted Entry/Exit Points - newser.com
Day 8 of Gains Streak for Viatris Stock with 6.9% Return (vs. -13% YTD) [10/22/2025] - Trefis
Goldman Sachs Adjusts Price Target on Viatris to $12 From $11, Maintains Neutral Rating - MarketScreener
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Relative strength of Viatris Inc. in sector analysis2025 Growth vs Value & Technical Pattern Recognition Alerts - newser.com
Can trapped investors hope for a rebound in Viatris Inc.2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
How Viatris is Fighting Infectious Disease - ACCESS Newswire
Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc - Insider Monkey
What the charts say about Viatris Inc. todayTrade Entry Report & High Conviction Trade Alerts - newser.com
World Mental Health Day 2025: Empowering Minds, Breaking Barriers - CSRwire
Viatris Inc. Stock Rises Monday, Outperforms Market - 富途牛牛
Viatris Inc. (VTRS) Stock Analysis: Navigating a 16.76% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Viatris buys Aculys Pharma to expand neurology portfolio in Japan - Medical Dialogues
Viatris Inc.’s volatility index tracking explainedMarket Risk Report & Real-Time Buy Signal Alerts - newser.com
How cyclical is Viatris Inc. (VIA) stock compared to rivals2025 Big Picture & Technical Entry and Exit Tips - nchmf.gov.vn
Is Viatris Inc. stock vulnerable to regulatory risksTreasury Yields & Free Weekly Watchlist of Top Performers - nchmf.gov.vn
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):